330 Participants NeededMy employer runs this trial

QUILS System for Lung Cancer Screening

Recruiting at 17 trial locations
SA
JA
TM
Overseen ByTimothy Mullett, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Timothy Mullett
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to improve lung cancer screening programs by using the QUILS System, a new screening tool, to enhance effectiveness and maintain patient engagement. The trial will audit current screening practices and provide feedback to improve quality. Doctors, nurses, and other staff involved in lung cancer screening programs will participate in surveys and feedback sessions. As an unphased trial, this study allows patients to contribute to developing more effective lung cancer screening methods.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that the QUILS System is safe for lung cancer screening?

Research has shown that the QUILS System enhances lung cancer screening programs. Studies indicate that it improves the quality and effectiveness of these programs. As the QUILS System optimizes screening rather than serving as a medical treatment, specific safety data is not available. It does not involve medication or medical procedures, so typical safety concerns do not apply. Instead, it focuses on refining the screening process, indirectly supporting better health outcomes.12345

Why are researchers excited about this trial?

Researchers are excited about the QUILS System for lung cancer screening because it offers a potentially more precise and less invasive way to detect lung cancer early. Unlike traditional methods like CT scans, which expose patients to radiation, the QUILS System may use advanced imaging and data analysis techniques to provide accurate results without the associated risks. This could lead to earlier detection and treatment, improving patient outcomes and reducing the need for more invasive procedures.

What evidence suggests that the QUILS System is effective for lung cancer screening?

Research has shown that the QUILS System can enhance lung cancer screening programs. One study found that programs using QUILS achieved quality scores ranging from 55% to 87%, with an average of 69%. This indicates that QUILS can help these programs operate more effectively. Additionally, programs using QUILS demonstrated overall improvements. By focusing on process enhancements, QUILS aims to make lung cancer screenings more effective, potentially leading to better patient outcomes.12678

Who Is on the Research Team?

TW

Timothy W Mullett, MD

Principal Investigator

University of Kentucky

Are You a Good Fit for This Trial?

This trial is for healthcare professionals and staff involved in running lung cancer screening programs, such as doctors, nurses, administrators, and others responsible for the program.

Inclusion Criteria

Participants in Lung Cancer Screening Program, including physicians, nurses, administrators and other staff responsible for the conduct of the program.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Audit

Enrolled programs undergo an audit for elements associated with improved quality and retention of patients in the screening process

4-6 weeks

Feedback and Process Improvement

A feedback report is delivered to identify priorities for process improvement

4 weeks

Follow-up

Participants are monitored for safety and effectiveness after the audit and feedback process

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • QUILS System

Trial Overview

The study tests the QUILS System—a process where lung cancer screening programs are reviewed and given feedback to help improve quality and keep patients engaged. It focuses on optimizing how these programs work.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: QUILS Kentucky Coalition InitativeExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Timothy Mullett

Lead Sponsor

Trials
2
Recruited
800+

Citations

EP.04A.03 Quality Implementation of Lung Cancer ...

Overall quality scores ranged from 55% to 87%, with an average score of 69% (SD=9%) across the ten sites evaluated. LCS Programs consistently received high ...

Systematic Review of Lung Cancer Screening - PMC - NIH

The National Lung Screening Trial (NLST) in the United States demonstrated a 20% reduction in lung cancer mortality with LDCT, and other trials confirmed its ...

CU Cancer Center Leader Jamie Studts, PhD, Receives ...

“We were able to show that quality improved overall across the 10 programs that participated in QUILS™,” Studts says. “You can see the outcomes ...

4.

quilsgroup.org

quilsgroup.org/

QUILS System: Home

We help you assess and improve the quality of your lung cancer screening program. The QUILS™ system empowers you to transform your screening program from st ...

Ongoing Research Looks at Optimizing Lung Cancer ... - ILCN

The ILST protocol outperformed NELSON and Lung-RADS with a positive predictive value of 17% versus 11% and 13%, respectively, she said. “The ...

Study Details | NCT07639255 | Kentucky - QUILS™ ...

This is an optimization pathway for lung cancer screening programs. Enrolled programs will undergo an audit for elements associated with ...

7.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/41687809/

Quality Implementation of Lung Cancer Screening System ...

A system to support high-quality delivery of lung cancer screening -cause mortality reductions

Kentucky Lung Cancer Screening Learning Collaborative

Data and Safety Monitoring Plan. Quality Implementation of Lung Cancer Screening (QUILSTM) system. series focuses on the equitable implementation of lung ...